- News & Features
Two studies presented on June 14 in Amsterdam at the Annual European Congress of Rheumatology spell promising results for lupus patients.
A study shows gout patients who received daily text messages reminding them to take their allopurinol were much likelier to take the uric acid-lowering medication than those who didn’t receive messages.
A cohort study presented at the Annual European Congress of Rheumatology on June 14 in Amsterdam found that patients who take tumour necrosis factor (TNF) inhibitors experience the least disease progression when they add nonsteroidal anti-inflammatory drugs (NSAIDs).
Lower levels of physical performance and more severe disease are associated with higher levels of depression in knee osteoarthritis patients.
New research found no difference in rates of cancer between rheumatoid arthritis patients who switched to the biologic tocilizumab and those who began taking a tumor necrosis factor (TNF) inhibitor.
Early, intensive treatment of rheumatoid arthritis can, in the long-term, bring mortality rates for RA patients in line with those rates in the general population.
Researchers have found that joint replacements decreased by more than half in RA patients between 1997 and 2010.
A new study indicates that two infusions of zoledronic acid -- one per year -- didn’t greatly reduce pain or bone marrow damage in knee osteoarthritis patients.
Patients who took canakinumab (Ilaris) reduced their gout rate by more than half, according to a new study.
Two studies presented on June 13 in Amsterdam at the 2018 Annual European Congress of Rheumatology better understand -- and perhaps even identify -- which at-risk patients will develop rheumatoid arthritis.